Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - olmesartan medoxomil; hydrochlorothiazide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (20+12.5)mg/tab - olmesartan medoxomil 20mg; hydrochlorothiazide 12,5mg - olmesartan medoxomil and diuretics

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

krka d.d., novo mesto, slovenia smarkeska cesta 6,, 8501 novo mest 386 7 3312 233 - olmesartan medoxomil; hydrochlorothiazide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (20+25)mg/tab - olmesartan medoxomil 20mg; hydrochlorothiazide 25mg - olmesartan medoxomil and diuretics

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

win medica ΦΑΡΜΑΚΕΥΤΙΚΗ ΑΝΩΝΥΜΗ ΕΤΑΙΡΕΙΑ Δ.Τ. win medica a.e. Οιδίποδος 1-3 & Παράδρομος Αττικής Οδού 33-35, 152 38 Χαλάνδρι 210.7488821 - olmesartan medoxomil; amlodipine besylate; hydrochlorothiazide - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (20+5+12.5)mg/tab - olmesartan medoxomil 20mg; amlodipine besylate 6,95mg; hydrochlorothiazide 12,5mg - olmesartan medoxomil, amlodipine and hydrochlorothiazide

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ΒΙΟΚΟΣΜΟΣ ΙΑΤΡΙΚΟΣ ΕΠΙΣΤΗΜΟΝΙΚΟΣ ΕΞΟΠΛΙΣΜΟΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. ΒΙΟΚΟΣΜΟΣ Α.Ε.Β.Ε. Θέση Πάνορμος Λαυρίου, 195 00 19500, Λαύριο Αττικής 22920.63900 - [18 f]-psma-1007 - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 20-4500 mbq/ml - [18 f]-psma-1007 20 - 4.500mbq - psma-1007 (18 f)

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

bennett ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. 16ο χλμ. Αθηνών-Λαμίας, 145 64 Κηφισιά 210.6254630 - rosuvastatin calcium; ezetimibe - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - (20+10)mg/tab - rosuvastatin calcium 20,8mg; ezetimibe 10mg - rosuvastatin and ezetimibe

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

demo abee 21 ΧΛΜ. ΕΘΝ.ΟΔΟΥ ΑΘΗΝΩΝ-ΛΑΜΙΑΣ, 145 68 145 68, ΚΡΥΟΝΕΡΙ 8161802 - ibandronate sodium - f.c.tab (ΕΠΙΚΑΛΥΜΜΕΝΟ ΜΕ ΛΕΠΤΟ ΥΜΕΝΙΟ ΔΙΣΚΙΟ) - 150mg/tab - ibandronate sodium 168,75mg - ibandronic acid

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Αντινεοπλασματικοί παράγοντες - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

meda pharmaceuticals s.a., greece (0000006749) Αγίου Δημητρίου 63, Αλιμος, 17456 - formoterol fumarate dihydrate - ΚΟΝΙΣ ΓΙΑ ΕΙΣΠΝΟΗ - 12mc/dose - ineof01061 formoterol fumarate dihydrate 0.012000 mg - formoterol

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

meda pharmaceuticals s.a., greece (0000006749) Αγίου Δημητρίου 63, Αλιμος, 17456 - formoterol fumarate dihydrate - ΚΟΝΙΣ ΓΙΑ ΕΙΣΠΝΟΗ - 6mc/dose - ineof01061 formoterol fumarate dihydrate 0.006000 mg - formoterol

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

ΒΙΑΝΕΞ Α.Ε. ΑΝΩΝΥΜΟΣ ΕΜΠΟΡΟΒΙΟΜΗΧΑΝΙΚΗ-ΤΟΥΡΙΣΤΙΚΗ-ΞΕΝΟΔΟΧΕΙΑΚΗ ΚΑΙ ΝΑΥΤΙΛΙΑΚΗ ΑΝΩΝΥΜΟΣ ΕΤΑΙΡΕΙΑ Δ.Τ. ΒΙΑΝΕΞ Α.Ε. (0000010313) Οδ - nebivolol hydrochloride - ΔΙΣΚΙΟ - 5mg/tab - ineof01005 nebivolol hydrochloride 5.450000 mg - nebivolol